Giorgio Arnaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5365074/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5593-5602.	3.6	1,184
2	A Survey on Adrenal Incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	723
3	A Survey on Adrenal Incidentaloma in Italy ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 637-644.	3.6	693
4	AME Position Statement on adrenal incidentaloma. European Journal of Endocrinology, 2011, 164, 851-870.	3.7	435
5	Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1541-1547.	3.6	284
6	High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology, 2004, 61, 768-777.	2.4	239
7	Approach to the Patient with Possible Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3121-3131.	3.6	219
8	Adrenal Incidentaloma: An Overview of Hormonal Data from the National Italian Study Group. Hormone Research, 1997, 47, 284-289.	1.8	159
9	AMPâ€activated protein kinase mediates glucocorticoid―induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB Journal, 2008, 22, 1672-1683.	0.5	148
10	Pathophysiology of Dyslipidemia in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 86-90.	2.5	147
11	GermlineNF1Mutational Spectra and Loss-of-Heterozygosity Analyses in Patients with Pheochromocytoma and Neurofibromatosis Type 1. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2784-2792.	3.6	126
12	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	11.4	116
13	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	3.6	113
14	Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5301-5306.	3.6	109
15	Expression Profiles for Steroidogenic Enzymes in Adrenocortical Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5446-5455.	3.6	104
16	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. Journal of Endocrinological Investigation, 2020, 43, 1141-1147.	3.3	103
17	Adrenal incidentaloma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2012, 26, 405-419.	4.7	94
18	Cardiovascular Risk In Cushing's Syndrome. Pituitary, 2004, 7, 253-256.	2.9	93

2

#	Article	IF	CITATIONS
19	Novel Somatic Mutations in the Catalytic Subunit of the Protein Kinase A as a Cause of Adrenal Cushing's Syndrome: A European Multicentric Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2093-E2100.	3.6	92
20	Italian Addison Network Study: Update of Diagnostic Criteria for the Etiological Classification of Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1598-1604.	3.6	83
21	Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5301-5306.	3.6	83
22	Changes in Adenosine 5â€2-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4969-4973.	3.6	76
23	MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS. Endocrinology and Metabolism Clinics of North America, 2000, 29, 107-125.	3.2	71
24	Use of the Desmopressin Test in the Differential Diagnosis of Pseudo-Cushing State from Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1115-1122.	3.6	70
25	Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications. Journal of Endocrinological Investigation, 2012, 35, 434-448.	3.3	69
26	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. European Journal of Endocrinology, 2017, 176, 453-461.	3.7	66
27	Hypertension-induced changes of platelet-derived growth factor receptor expression in rat aorta and heart Hypertension, 1991, 17, 888-895.	2.7	65
28	Cyclical Cushing's Syndrome in a Patient with a Bronchial Neuroendocrine Tumor (Typical Carcinoid) Expressing Ghrelin and Growth Hormone Secretagogue Receptors. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5834-5840.	3.6	64
29	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. Journal of Endocrinological Investigation, 2012, 35, 817-23.	3.3	64
30	Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. European Journal of Endocrinology, 2002, 146, 303-309.	3.7	63
31	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. Endocrine, 2017, 55, 959-968.	2.3	62
32	Harmful effects of functional hypercortisolism: a working hypothesis. Endocrine, 2014, 46, 370-386.	2.3	60
33	Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2029-2035.	3.6	59
34	Variable Expression of the V1 Vasopressin Receptor Modulates the Phenotypic Response of Steroid-Secreting Adrenocortical Tumors1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2029-2035.	3.6	58
35	Coenzyme Q10 levels in idiopathic and varicocele-associated asthenozoospermia. Andrologia, 2002, 34, 107-111.	2.1	58
36	Laparoscopic adrenalectomy: a report on 50 operations. European Journal of Endocrinology, 1998, 138, 548-553.	3.7	57

#	Article	IF	CITATIONS
37	Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clinical Endocrinology, 2003, 58, 725-731.	2.4	55
38	Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. Clinical Endocrinology, 2002, 57, 587-593.	2.4	53
39	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. European Journal of Endocrinology, 2010, 163, 369-376.	3.7	53
40	Pegvisomant in acromegaly: an update. Journal of Endocrinological Investigation, 2017, 40, 577-589.	3.3	53
41	Self image and quality of life in acromegaly. Pituitary, 2002, 5, 17-19.	2.9	52
42	Coagulopathy in Cushing's Syndrome. Neuroendocrinology, 2010, 92, 55-59.	2.5	52
43	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. Pituitary, 2016, 19, 488-495.	2.9	52
44	High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2454-2464.	3.6	51
45	Targeting Estrogen Receptor-α Reduces Adrenocortical Cancer (ACC) Cell Growthin Vitroandin Vivo: Potential Therapeutic Role of Selective Estrogen Receptor Modulators (SERMs) for ACC Treatment. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2238-E2250.	3.6	50
46	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	5.1	47
47	Expression of the Novel Adrenocorticotropin-Responsive Gene Selective Alzheimer's Disease Indicator-1 in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1332-1339.	3.6	46
48	Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome. European Journal of Endocrinology, 2012, 166, 35-42.	3.7	46
49	Bone complications in patients with Cushing's syndrome: looking for clinical, biochemical, and genetic determinants. Osteoporosis International, 2014, 25, 913-921.	3.1	44
50	First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment) Tj ETQq0 Endocrinological Investigation, 2006, 29, 1017-1020.	0 0 rgBT / 3.3	Overlock 10 43
51	Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. Journal of Endocrinological Investigation, 2009, 32, 202-209.	3.3	43
52	Effects of hypertension and aging on platelet-derived growth factor and platelet-derived growth factor receptor expression in rat aorta and heart Hypertension, 1991, 18, III93-9.	2.7	43
53	Apparent mineralocorticoid excess type II. Steroids, 1994, 59, 80-83.	1.8	42
54	Adrenal incidentaloma. Brazilian Journal of Medical and Biological Research, 2000, 33, 1177-1189.	1.5	42

#	Article	IF	CITATIONS
55	Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E165-E172.	3.6	41
56	Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine, 2017, 57, 156-165.	2.3	40
57	Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis. European Journal of Endocrinology, 2009, 160, 891-898.	3.7	38
58	Reduced expression of the growth hormone and type 1 insulinâ€like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology, 2003, 59, 328-338.	2.4	37
59	Corticotrophin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clinical Endocrinology, 2011, 75, 666-672.	2.4	37
60	Glucocorticoid excess and COVID-19 disease. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 703-714.	5.7	36
61	Pegvisomant in acromegaly: Why, when, how. Journal of Endocrinological Investigation, 2007, 30, 693-699.	3.3	35
62	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. European Journal of Endocrinology, 2010, 162, 361-369.	3.7	35
63	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. Endocrine, 2016, 52, 322-332.	2.3	35
64	Acth receptor mRNA in human adrenocortical tumors: Overexpression in aldosteronomas. Endocrine Research, 1998, 24, 845-849.	1.2	34
65	Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. Cancer Gene Therapy, 2015, 22, 9-16.	4.6	34
66	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1872-1879.	3.6	34
67	Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. Journal of Endocrinological Investigation, 2020, 43, 683-696.	3.3	34
68	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on "real-world evidence― Endocrine, 2019, 64, 657-672.	2.3	33
69	Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4207-4211.	3.6	32
70	Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. American Journal of Hypertension, 2001, 14, 62-65.	2.0	32
71	Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: Relationship with cell proliferation. Experimental Cell Research, 2008, 314, 123-130.	2.6	32
72	The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome. Endocrine, 2017, 55, 564-572.	2.3	32

#	Article	IF	CITATIONS
73	Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 468-470.	3.6	31
74	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. Journal of Clinical Medicine, 2019, 8, 1850.	2.4	31
75	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. Endocrine, 2016, 54, 762-767.	2.3	30
76	Adrenal incidentaloma: Surgical update. Journal of Endocrinological Investigation, 2007, 30, 200-204.	3.3	28
77	Sexual Dysfunctions in Men Affected by Autoimmune Addison's Disease Before and After Short-Term Gluco- and Mineralocorticoid Replacement Therapy. Journal of Sexual Medicine, 2013, 10, 2036-2043.	0.6	28
78	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). Journal of Endocrinological Investigation, 2018, 41, 3-19.	3.3	28
79	The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study. Journal of Endocrinological Investigation, 2019, 42, 327-335.	3.3	28
80	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. Cancers, 2020, 12, 740.	3.7	28
81	Investigation protocol: adrenal enlargement. Clinical Endocrinology, 1999, 50, 141-146.	2.4	27
82	A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome. Hormone and Metabolic Research, 2016, 48, 290-298.	1.5	26
83	Up-to 5-year efficacy of pasireotide in a patient with Cushing's disease and pre-existing diabetes: literature review and clinical practice considerations. Pituitary, 2015, 18, 359-365.	2.9	25
84	Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 2542-2546.	2.4	24
85	<scp>ACROSCORE</scp> : a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. Clinical Endocrinology, 2016, 84, 380-385.	2.4	24
86	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	3.6	24
87	Variable Expression of the Transcription Factors cAMP Response Element-Binding Protein and Inducible cAMP Early Repressor in the Normal Adrenal Cortex and in Adrenocortical Adenomas and Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5443-5449.	3.6	22
88	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. Endocrine, 2017, 56, 298-307.	2.3	22
89	Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4207-4211.	3.6	22
90	A novel endothelial tyrosine kinase cDNA homologous to platelet-derived growth factor receptor cDNA. Biochemical and Biophysical Research Communications, 1992, 186, 706-714.	2.1	21

#	Article	IF	CITATIONS
91	Increased frequency of the rs2066853 variant of aryl hydrocarbon receptor gene in patients with acromegaly. Clinical Endocrinology, 2014, 81, 249-253.	2.4	21
92	Transforming growth factor-ß1 is more expressed in thyroid follicular adenoma than in normal tissue. Journal of Endocrinological Investigation, 1994, 17, 335-340.	3.3	20
93	Enhanced expression of transforming growth factor β1 in rat thyroid hyperplasia is thyrotropin induced and time dependent. European Journal of Endocrinology, 1996, 134, 373-378.	3.7	20
94	Effects of long-term treatment with human pure follicle-stimulating hormone on semen parameters and sperm-cell ultrastructure in idiopathic oligoteratoasthenozoospermia. Andrologia, 2000, 32, 155-161.	2.1	20
95	Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease. Pituitary, 2015, 18, 60-67.	2.9	20
96	Impact of COVID-19 pandemic on psychophysical stress in patients with adrenal insufficiency: the CORTI-COVID study. Journal of Endocrinological Investigation, 2021, 44, 1075-1084.	3.3	20
97	Laurdanâ^—â^—Laurdan, Molecular Probes, Eugene, Oregon. fluorescence: a simple method to evaluate sperm plasma membrane alterations. Fertility and Sterility, 2001, 76, 501-505.	1.0	19
98	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTHâ€dependent Cushing's syndrome. Clinical Endocrinology, 2017, 87, 500-507.	2.4	19
99	Adrenal morpho-functional alterations in patients with acromegaly. Journal of Endocrinological Investigation, 2008, 31, 602-606.	3.3	18
100	Pasireotide for the treatment of Cushing's disease. Expert Opinion on Investigational Drugs, 2010, 19, 889-898.	4.1	18
101	How to improve effectiveness of pegvisomant treatment in acromegalic patients. Journal of Endocrinological Investigation, 2018, 41, 575-581.	3.3	18
102	Pituitary adenomas, stem cells, and cancer stem cells: what's new?. Journal of Endocrinological Investigation, 2018, 41, 745-753.	3.3	17
103	Decreased expression of insulin-sensitive glucose transporter mRNA (GLUT-4) in adipose tissue of non-insulin-dependent diabetic and obese patients: Evaluation by a simplified quantitative PCR assay. Journal of Endocrinological Investigation, 1994, 17, 709-715.	3.3	16
104	Severe hypomagnesaemia-induced hypocalcaemia in a patient with Gitelman's syndrome. Clinical Endocrinology, 2002, 56, 413-418.	2.4	16
105	Vasopressin receptors modulate the pharmacological phenotypes of cushing's syndrome. Endocrine Research, 1998, 24, 807-816.	1.2	15
106	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. Frontiers in Endocrinology, 2021, 12, 595894.	3.5	15
107	Functional and Nonfunctional Adrenocortical Tumors Demonstrate a High Responsiveness to Low-Dose Adrenocorticotropin. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1994-1998.	3.6	14
108	Androgens in Cushing's Syndrome. Frontiers of Hormone Research, 2019, 53, 77-91.	1.0	14

#	Article	IF	CITATIONS
109	Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. Clinical Endocrinology, 2005, 62, 533-538.	2.4	13
110	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. Endocrine, 2015, 50, 154-161.	2.3	12
111	Hypothalamic–Pituitary Diseases and Erectile Dysfunction. Journal of Clinical Medicine, 2021, 10, 2551.	2.4	12
112	Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas. Pituitary, 2017, 20, 251-260.	2.9	11
113	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. European Journal of Endocrinology, 2021, 184, R51-R59.	3.7	11
114	Telomerase Activity Is Significantly Enhanced in Malignant Adrenocortical Tumors in Comparison to Benign Adrenocortical Adenomas. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 468-470.	3.6	11
115	Fine-needle aspiration cytology of adrenal masses: a re-assessment with histological confirmation. Journal of Endocrinological Investigation, 2012, 35, 590-4.	3.3	11
116	Intrapituitary cytokines in Cushing's disease: do they play a role?. Pituitary, 2011, 14, 236-241.	2.9	10
117	Ultrasound-based detection of glucocorticoid-induced impairments of muscle mass and structure in Cushing's disease. Journal of Endocrinological Investigation, 2019, 42, 757-768.	3.3	10
118	Acromegaly and male sexual health. Reviews in Endocrine and Metabolic Disorders, 2022, 23, 671-678.	5.7	10
119	Sodium alterations impair the prognosis of hospitalized patients with COVID-19 pneumonia. Endocrine Connections, 2021, 10, 1344-1351.	1.9	8
120	New treatment guidelines on Cushing's disease. F1000 Medicine Reports, 2009, 1, .	2.9	7
121	Fracture risk assessment before and after resolution of endogenous hypercortisolism: Is the FRAX® algorithm useful?. Journal of Endocrinological Investigation, 2014, 37, 957-965.	3.3	7
122	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Pituitary, 2020, 23, 534-542.	2.9	7
123	MTHFRÂC677T polymorphism, folate status and colon cancer risk in acromegalic patients. Pituitary, 2014, 17, 257-66.	2.9	6
124	Angiotensin II Receptors in Cortical and Medullary Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 865-869.	3.6	6
125	Transforming Growth Factor Î ² 1: Implications in Adrenocortical Tumorigenesis. Endocrine Research, 2000, 26, 905-910.	1.2	5
126	Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study. Journal of Endocrinological Investigation, 2017, 40, 669-678.	3.3	5

#	Article	IF	CITATIONS
127	Copeptin and Stress. Endocrines, 2021, 2, 384-404.	1.0	5
128	Unusual clinical manifestation of pheochromocytoma in a MEN2A patient. Journal of Endocrinological Investigation, 2002, 25, 53-57.	3.3	4
129	Advances in medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2007, 2, 735-743.	2.4	4
130	Somatic PRKACA Mutations: Association With Transition From Pituitary-Dependent to Adrenal-Dependent Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5651-5657.	3.6	4
131	Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance. Frontiers in Cell and Developmental Biology, 2019, 7, 227.	3.7	4
132	Personality (at Intrapsychic and Interpersonal Level) Associated With Quality of Life in Patients With Cancer (Lung and Colon). Cancer Control, 2019, 26, 107327481988056.	1.8	4
133	Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population. Journal of Endocrinological Investigation, 2021, 44, 327-337.	3.3	4
134	COVID-19 and endocrine and metabolic disorders: critical points and suggestions for a correct therapeutic management from a tertiary endocrine center in Italy. Minerva Endocrinology, 2022, 47, .	1.1	4
135	Mesenchymal Stem Cells Exposed to Persistently High Glucocorticoid Levels Develop Insulin-Resistance and Altered Lipolysis: A Promising In Vitro Model to Study Cushing's Syndrome. Frontiers in Endocrinology, 2022, 13, 816229.	3.5	4
136	Update on Hypercortisolism Therapy. Frontiers of Hormone Research, 2016, 46, 87-105.	1.0	3
137	Mutational analysis of StAR gene in adrenal tumors. International Journal of Cancer, 2002, 97, 357-360.	5.1	2
138	Osilodrostat oral tablets for adults with Cushing's disease. Expert Review of Endocrinology and Metabolism, 2022, , 1-11.	2.4	2
139	Pituitary-directed medical treatment of Cushing's disease. Expert Review of Endocrinology and Metabolism, 2009, 4, 263-272.	2.4	1
140	Masse surrenaliche incidentali: protocollo diagnostico. L Endocrinologo, 2000, 1, 55-62.	0.0	0
141	Somatic Mutation Analysis of the MEN1 Gene in Adrenocortical Tumors Using Denaturing Gradient Gel Electrophoresis (DGGE). International Journal on Disability and Human Development, 2001, 2, .	0.2	0
142	Diagnosi della sindrome di Cushing. L Endocrinologo, 2005, 6, 137-142.	0.0	0
143	Histological Contamination in Clinical Research—from Ultrastructure to Stem Cell Biology. , 2020, , 57-69.		0